Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Procter & Gamble and Sanofi Aventis, who co-market Actonel for the treatment of osteoporosis, have launched a lawsuit against Roche and GlaxoSmithKline who co-market Boniva, a rival osteoporosis medicine.
Subscribe to our email newsletter
The plaintiffs allege that the advertising for the GSK / Roche product misleads consumers and physicians about the benefits of the drug, specifically that the advertising for Boniva falsely claims that the drug has been proven to reduce the risk of nonspinal fractures in osteoporosis patients.
Procter & Gamble and Sanofi Aventis say that this claim has not been proven in clinical trials of Boniva, whereas their own Actonel medication has been proven to reduce the risk of non-spinal fractures after three years.
Both Actonel and Boniva have been proven to reduce the risk of spinal fractures at three years in women with postmenopausal osteoporosis. The medications have never been compared in head-to-head clinical studies.